Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
2,061 stopped studies mapped to Malignant Neoplasm of Unknown Primary and descendants · 91% state a reason
Over the 2,061 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03809624 | Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors…(PDL1x41BB) | Phase 1 | terminated | Jan 18, 2019 | Inhibrx Biosciences, Inc | Program terminated due to lack of meaningful efficacy signal. | Efficacy / futility |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03592264 | A Phase I/II Study of OBI-3424 in Subjects with Advanced Solid Tumors | Phase 1 / Phase 2 | terminated | Jul 19, 2018 | OBI Pharma, Inc | Little evidence of clinical activity in tumor types enrolled | Enrollment / accrual |
| NCT03821376 | Correlation of Renal Mass Pathologic Grade and Contrast Enhanced Ultrasound (CEUS) | Phase 4 | terminated | Jan 29, 2019 | Indiana University | Study stopped due to staffing issues that impacted ability to recruit. | Enrollment / accrual |
| NCT03879798 | DS-3201b and Irinotecan for Patients With Recurrent Small Cell Lung Cancer | Phase 1 / Phase 2 | terminated | Mar 19, 2019 | Memorial Sloan Kettering Cancer Center | Due to DLTs | Other (stated, no rule matched) |
| NCT03207867 | A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and… | Phase 2 | terminated | Jul 5, 2017 | Novartis Pharmaceuticals | Sponsor decision | Sponsor / business decision |
| NCT03452137 | A Study of Atezolizumab (Anti-PD-L1 Antibody) as Adjuvant Therapy After Definitive Local…(IMvoke010) | Phase 3 | terminated | Mar 2, 2018 | Hoffmann-La Roche | Decision to terminate the study as its primary endpoint of investigator-assessed event free… | Safety / toxicity |
| NCT03872388 | Atorvastatin in Treating Patients With Stage IIb-III Triple Negative Breast Cancer Who… | Phase 2 | terminated | Mar 13, 2019 | M.D. Anderson Cancer Center | Due to slow accrual | Enrollment / accrual |
| NCT04683939 | Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy Trial of BNT141 in… | Phase 1 / Phase 2 | terminated | Dec 24, 2020 | BioNTech SE | Sponsor decision | Sponsor / business decision |
| NCT06427369 | An Investigational Scan (124I-hJAA-F11 PET/CT) for Diagnosing Lung Cancer | Phase 1 | withdrawn | May 23, 2024 | Roswell Park Cancer Institute | prioritization | Other (stated, no rule matched) |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk… | N/A | withdrawn | Sep 19, 2018 | Fudan University | This study was not approved by the Ethics Committee | Other (stated, no rule matched) |
| NCT05191797 | Bomedemstat and Maintenance Immunotherapy for Treatment of Newly Diagnosed Extensive… | Phase 1 / Phase 2 | terminated | Jan 14, 2022 | University of Washington | Closed per SRC Low Accrual Policy | Enrollment / accrual |
| NCT00667628 | Phase 2 Study of TAC-101 Combined With Transcatheter Arterial Chemoembolization (TACE)… | Phase 2 | terminated | Apr 28, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
| NCT00687596 | Study of TAC-101 as Second Line Treatment in Patients With Advanced Hepatocellular… | Phase 2 | terminated | Jun 2, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns | Safety / toxicity |
| NCT04685798 | Optimized Diffusion-Weighted Imaging for the Evaluation of Post-Treatment Squamous Cell… | N/A | terminated | Dec 28, 2020 | Washington University School of Medicine | Low accrual | Enrollment / accrual |
| NCT05356897 | Tucatinib Combined with Trastuzumab and TAS-102 for the Treatment of HER2 Positive… | Phase 2 | withdrawn | May 2, 2022 | Academic and Community Cancer Research United | no sites were regulatory ready and the SC took the study to a different group. | Other (stated, no rule matched) |
| NCT05641545 | IVAC-RCC-001: A Personalized Neoantigen Vaccine as Add-on to Standard of Care Checkpoint… | Phase 1 | terminated | Dec 7, 2022 | SLK Kliniken Heilbronn GmbH | Premature discontinuation due to üoor participant recruitment | Enrollment / accrual |
| NCT05655598 | TAS-116 Plus Palbociclib in Breast and Rb-null Cancer | Phase 1 | withdrawn | Dec 19, 2022 | Brown University | Lack of accrual | Enrollment / accrual |
| NCT05679388 | A Study of Extending Relugolix Dosing Intervals Through Addition of Itraconazole or… | Phase 1 | terminated | Jan 11, 2023 | University of Chicago | Terminated by the PI | Other (stated, no rule matched) |
| NCT01904253 | A Phase 2 Study Comparing TAS-102 Versus Topotecan or Amrubicin to Treat Small Cell Lung… | Phase 2 | terminated | Jul 22, 2013 | Taiho Oncology, Inc. | The preliminary data does not suggest any safety signal, but an ad hoc interim analysis showed an… | Safety / toxicity |
| NCT03370861 | How Microbes and Metabolism May Predict Skin Cancer Immunotherapy Outcomes(MINING) | — | terminated | Dec 12, 2017 | Washington University School of Medicine | Subject recruitment was limited severely by the 2020-2023 COVID-19 pandemic, which led this study… | COVID-19 / pandemic |
| NCT00756782 | A Study of TAC-101 in Combination With TACE Versus TACE Alone in Asian Patients With… | Phase 2 | withdrawn | Sep 22, 2008 | Taiho Oncology, Inc. | Terminated due to safety concerns. | Safety / toxicity |
| NCT03552380 | Study of Entinostat With Nivolumab Plus Ipilimumab in Previously Treated Renal Cell… | Phase 2 | terminated | Jun 11, 2018 | Roberto Pili | Funder halted development of compound in this disease | Other (stated, no rule matched) |
| NCT04944173 | SCION: SABR and Checkpoint Inhibition of NSCLC(SCION) | Phase 2 | withdrawn | Jun 29, 2021 | University of British Columbia | Overestimated pool of eligible patients and the potential participants either declined… | Other (stated, no rule matched) |
| NCT01284348 | To Determine Safe and Effective Dose of Sotatercept for the Treatment of Chemotherapy… | Phase 2 | terminated | Jan 27, 2011 | Merck Sharp & Dohme LLC | Persistent low enrollment made study continuation no longer feasible | Enrollment / accrual |
| NCT03960008 | Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as…(SBRTvsTACE) | Phase 3 | terminated | May 22, 2019 | Lahey Clinic | This study was closed early due to lack of enrollments and insufficient funding. | Enrollment / accrual |
| NCT04123704 | Sitravatinib in Metastatic Breast Cancer | Phase 2 | terminated | Oct 11, 2019 | Xiang Zhang | Terminated by sponsor due to lack of interest | Other (stated, no rule matched) |
| NCT04835597 | Precision Performance Status Assessment in Breast Cancer Patients Receiving Neoadjuvant… | — | terminated | Apr 8, 2021 | M.D. Anderson Cancer Center | IRB Study Closure | Other (stated, no rule matched) |
| NCT06006286 | A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally… | Phase 1 / Phase 2 | withdrawn | Aug 23, 2023 | M.D. Anderson Cancer Center | 0 participants registered | Other (stated, no rule matched) |
| NCT00791154 | QUILT-2.013: First-Line Treatment for Extensive Stage Small Cell Lung Cancer(SCLC) | Phase 1 / Phase 2 | terminated | Nov 14, 2008 | NantCell, Inc. | Subjects discontinued study | Other (stated, no rule matched) |
| NCT03674827 | Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC | Phase 1 | terminated | Sep 18, 2018 | Pfizer | The study was terminated due to the review of the asset (VBIR-2) within the Sponsor's oncology… | Safety / toxicity |
| NCT03498716 | A Study Comparing Atezolizumab (Anti PD-L1 Antibody) In Combination With Adjuvant…(IMpassion030) | Phase 3 | terminated | Apr 17, 2018 | Hoffmann-La Roche | The study was terminated by the sponsor following interim analysis as the primary endpoint of iDFS… | Efficacy / futility |
| NCT04205786 | Vitamin B12 for Aromatase Inhibitors Associated Musculoskeletal Symptoms in Breast Cancer | N/A | withdrawn | Dec 19, 2019 | Case Comprehensive Cancer Center | Logistics requirements, research cancelled | Other (stated, no rule matched) |
| NCT02037529 | Eribulin Mesylate or Paclitaxel as First- or Second-Line Therapy in Treating Patients… | Phase 3 | suspended | Jan 16, 2014 | Academic and Community Cancer Research United | Total enrollment number is being lowered | Enrollment / accrual |
| NCT06110598 | CAPEcitabine eXtension of Adjuvant Therapy for Pancreatic Adenocarcinoma: (CAPE-X) | Phase 2 | withdrawn | Oct 31, 2023 | Case Comprehensive Cancer Center | PI left the institution | Investigator |
| NCT06206278 | Evaluation of Infigratinib in Patients With Locally Advanced or Metastatic Gastric Cancer… | Phase 2 | terminated | Jan 16, 2024 | LianBio LLC | Business Reason | Sponsor / business decision |
| NCT03387085 | QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03853317 | QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma… | Phase 2 | terminated | Feb 25, 2019 | ImmunityBio, Inc. | Not meeting recruitment goal | Enrollment / accrual |
| NCT05352542 | GPC3-targeting CART Cell in Treatment of Advanced Hepatocellular Carcinoma | Phase 1 | terminated | Apr 29, 2022 | jianming xu | achieve the proof of concept | Other (stated, no rule matched) |
| NCT06337162 | Pre-Transplant INCBB099280 for Hepatocellular Carcinoma (HCC)(HCC) | Phase 1 | withdrawn | Mar 29, 2024 | Abramson Cancer Center at Penn Medicine | Incyte made a strategic business decision to stop enrollment to all ongoing oral PD-L1 (99280)… | Enrollment / accrual |
| NCT05001282 | A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor… | Phase 1 / Phase 2 | terminated | Aug 11, 2021 | Elucida Oncology | Lack of Funding - no safety issue with Drug; Company Permanently Closed | Safety / toxicity |
| NCT04497038 | Cabozantinib in Patients With Advanced Hepatocellular Carcinoma With Child Pugh Class B… | Phase 1 / Phase 2 | terminated | Aug 4, 2020 | University of Michigan Rogel Cancer Center | loss of funding | Funding |
| NCT03387111 | QUILT-3.090: NANT Squamous Cell Carcinoma (SCC) Vaccine: Subjects With SCC Who Have… | Phase 1 / Phase 2 | terminated | Dec 29, 2017 | ImmunityBio, Inc. | Study halted prematurely and will not resume; participants are no longer being examined or… | Other (stated, no rule matched) |
| NCT03423264 | PROGRESS Trial - Prophylactic Gabapentin for Relief of Symptoms and Improved Swallowing | Phase 2 | withdrawn | Feb 6, 2018 | University of Chicago | unable to accrue | Enrollment / accrual |
| NCT04931420 | Study Comparing Standard of Care Chemotherapy With/ Without Sequential Cytoreductive… | Phase 2 | withdrawn | Jun 18, 2021 | University of Chicago | PI left site | Investigator |
| NCT04628780 | Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid… | Phase 1 | terminated | Nov 16, 2020 | Pfizer | Pfizer has made an internal business decision to not continue further development of PF-07209960.… | Safety / toxicity |
| NCT06384820 | Study of Cemiplimab Alone or in Combination With Fianlimab and/or Other Experimental… | Phase 2 | withdrawn | Apr 25, 2024 | Regeneron Pharmaceuticals | Business Decision | Sponsor / business decision |
| NCT06084845 | Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy… | Phase 2 | withdrawn | Oct 16, 2023 | ECOG-ACRIN Cancer Research Group | A phase III trial of the investigational agent failed to pass futility boundaries at interim… | Efficacy / futility |
| NCT04212221 | MGD013 Monotherapy and Combination With Brivanib Dose Escalation and Expansion Study in… | Phase 1 / Phase 2 | terminated | Dec 26, 2019 | Zai Lab (Shanghai) Co., Ltd. | Due to the rapid shifting of liver cancer disease landscape and the company's adjustment of… | Sponsor / business decision |
| NCT06398587 | Onvansertib in Combination With Gemcitabine and Nab-paclitaxel for the Treatment of… | Phase 2 | withdrawn | May 3, 2024 | OHSU Knight Cancer Institute | Sponsor withdrawal | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Oct 23, 2024source: clinicaltrials